Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07066995 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Study acronym: BAH2573-102
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Autologous T-cells engineered to express CARs targeting Mesothelin and Claudin18.2, for Unresectable locally advanced or metastatic pancreatic adenocarcinoma (Pancreatic Ductal Adenocarcinoma, PDAC), administered as two separate sequential infusions following lymphodepleting chemotherapy
Trial Details
NCT Number NCT07066995
Lead Sponsor Essen Biotech
Conditions
(from sponsor)		 Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
Related terms Pancreatic Neoplasms
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov